UNSPSC 51284134: Cefodizime sodium

This classification denotes a beta-lactam antibacterial with the molecular formula C20H18N6O7S4.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HC1T51593A, chemically known as (z)-7-(2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido)-3-(5-carboxymethyl-4-methylthiazol-2-ylthiomethyl)-3-cephem-4-carboxylic acid, disodium salt, but more generally known as cefodizime sodium, which bears US NIH Compound Identifier 9576734.

UNSPSC 51284134 Cefodizime sodium is a Commodity code that nominally covers a specific injectable antibiotic, but recent state and local opportunities do not show procurement activity aligned with this narrow pharmaceutical scope. The most recent opportunities tagged to this code involve substantially broader medical and pharmacy supply categories—including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and first-aid supplies for emergency response operations. The mismatch suggests either classification error in the source opportunities or that this code has become a catch-all tag for pharmaceutical and medical supply procurement more broadly. Actual buying activity under recent opportunities spans naloxone distribution for public health, emergency medical supplies for fire-rescue operations, generic pharmaceutical contracting through state purchasing cooperatives, and direct-to-manufacturer pharmacy benefit programs. Issuing bodies include county health departments, municipal fire services, state health and human services commissions, and multistate cooperative purchasing alliances (MMCAP) serving state and local facilities across multiple jurisdictions.

Geographic activity centers on Florida, Minnesota, Texas, and Oregon, with the most recent opportunities posted in the first half of 2026. The City of Tampa issued an IFB for medical and first aid supplies (Bid 26-P-00145) with a $700,000 estimated contract value and response due March 13, 2026, designated as a sheltered-market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. Seminole County, Florida solicited naloxone and safe drug deactivation systems (IFB 60459723LAS) for 1,900 and 800 units respectively on annual basis with quarterly deliveries, bid due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, serving participating state and local government facilities in Minnesota and Oregon. Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to explore direct-to-manufacturer prescription programs, gathering vendor capabilities before issuing a formal RFP.